title: The evolving role of prostate brachytherapy.
abstract: BACKGROUND
  The publication of several large studies with long-term results on the use of prostate brachytherapy has resulted in increased use of this option for patients with localized prostate cancer.
  
  
  METHODS
  A historical review of brachytherapy as an approach to prostate cancer management is provided, as well as a general summary of the implant technique and the results to date according to patient risk. The effects of combination therapies for specific patient groups are also reviewed.
  
  
  RESULTS
  A recent 12-year follow-up reported no failures after 10 years, and 75% of recurrences occurred with-in the first 5 years. Patients at low risk for failure based on stage, grade, and prostate-specific antigen (PSA) parameters are likely to have disease confined to the prostate. Those with more advanced disease are likely to have a lower probability of cure with brachytherapy as monotherapy. Complications involve primarily the urinary tract. Ideal candidates have a PSA of =10, Gleason score of =7, and low-volume/low-stage disease (stage T1c or T2a). Patients with more-advanced disease are candidates for brachytherapy combined with external-beam radiation therapy (EBRT). For high-risk men with multiple adverse prognostic features, consideration should be given to clinical trials investigating innovative treatment combinations (eg, the addition of androgen blockade, and EBRT).
  
  
  CONCLUSIONS
  The rarity of failures after 5 years and the absence of recurrence after 10 years suggest a that brachytherapy for localized prostate cancer can provide durable disease control. Future improvements in pathologic tools may lead to selection of patients more likely to respond well to brachytherapy.
authors.affiliation: Arizona Oncology Services, 8994 E. Desert Cove Avenue, Suite 100, Scottsdale 85260. dbeyer@azoncology.com
authors.forename: D C
authors.initials: DC
authors.lastname: Beyer
mesh_terms: D001918:Brachytherapy; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000401:mortality / Q000532:radiotherapy*; D015996:Survival Rate
chemical_list: D017430:Prostate-Specific Antigen